Atara Biotherapeutics, Inc.
ATRADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ATRA Earnings Report
FQ end 2026-06
How ATRA's past catalysts played out
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-induced Lymphomas
EBV-specific T cells (EBV-CTLs)
EBV-induced Lymphomas
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Atara Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Atara Biotherapeutics, Inc.'s (ATRA) pipeline across Phase 2. Its lead program is Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Atara Biotherapeutics, Inc.'s next FDA catalyst?→
Atara Biotherapeutics, Inc.'s (ATRA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATRA biotech catalysts?→
Add ATRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Atara Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.